There is growing evidence that patients with gBRCA ER+/HER2- advanced breast cancer are at higher risk of early disease progression under CDK4/6 inhibitors than their counterparts with wild-type BRCA disease [30,31]. This evidence concerns the gene ERBB2 and breast carcinoma.